- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04142229
Artificial Pancreas With Different Stress Assessments in the Outpatient Setting
November 28, 2020 updated by: Sansum Diabetes Research Institute
A Randomized Crossover Comparison of Artificial Pancreas vs. Sensor Augmented Pump/Predictive Low Glucose Suspend With Different Stress Assessments in the Outpatient Setting for Patients With Type 1 Diabetes
This feasibility study is a randomized crossover trial that will compare the efficacy and safety of an automated insulin delivery (AID) system in patients with type 1 diabetes using a Model Predictive Control (MPC) algorithm versus sensor augmented pump therapy (SAP)/Predictive Low Glucose Suspend (PLGS), and will include different stress induction and assessments over a 4 week period.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Eligible participants will be randomly assigned to one of two treatment arms: 1) AID for two weeks and SAP/PLGS for two weeks , or 2) SAP/PLGS for two weeks and AID for two weeks.
During the 4-week trial, subjects will wear the Empatica E4 wristband every day to record electrodermal activity, accelerometer and heartrate data.
Subjects will also complete logbooks to record activity and stress.
During each two-week period, subjects will come to the clinical center twice for stress induction tests in a medically supervised setting.
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Santa Barbara, California, United States, 93105
- Sansum Diabetes Research Institute
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year and using insulin for at least 1 year
- Using an insulin pump for at least 3 months at the time of screening. Insulin pump use includes use of automated features, to include predictive or threshold low-glucose suspend or hybrid closed-loop with or without a Dexcom sensor.
- Familiarity and use of a carbohydrate ratio for meal boluses.
- Age ≥18.0 years old
- HbA1c < 10.5%, as performed by point of care or central laboratory testing. HbA1c will be assessed at the screening visit, or if already completed within 2 weeks of the screening visit, the prior lab value may be used in lieu of repeating this assessment.
- For females, not currently known to be pregnant. If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study and up to one month afterwards. A negative serum or urine pregnancy test will be required for all females of child-bearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.
- Willingness to switch home pump to PLGS or full manual mode if using hybrid - Investigator has confidence that the participant can successfully operate all study devices and is capable of adhering to the protocol.
- Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already, and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the study.
- Willingness not to start any new non-insulin glucose-lowering agent during the course of the trial.
Exclusion Criteria:
- Use of an unapproved closed-loop insulin delivery system within 2 weeks before screening or during the study is not allowed.
- Have a blood pressure at screening outside the range of 160 mmHg systolic blood pressure and/or greater than 100 mmHg for diastolic blood pressure (if repeated measurements are within this range, the patient may be included in the study)
- Have coronary artery disease that is not stable with medical management, including unstable angina, angina that prevents moderate exercise despite medical management, or within the last 12 months before screening a history of myocardial infarction, percutaneous coronary intervention, enzymatic lysis of a presumed coronary occlusion, or coronary artery bypass grafting
- Concurrent use of Afrezza or any non-insulin glucose-lowering agent other than metformin (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas).
- Hemophilia or any other bleeding disorder
A condition, which in the opinion of the investigator or designee, would put the participant or study at risk, to include:
- Pregnancy, or planning pregnancy within 1 month of completing the clinical trial.
- Allergy or hypersensitivity to hydrocortisone, or any component of the formulation
- Presence of a known adrenal disorder
- Systemic fungal infections
- Active infection of any kind, or at risk of infection (susceptibility to infection) from known immunosuppression or underlying immunosuppressed condition
- Idiopathic thrombocytopenia purpura (ITP)
- Varicella
- Glaucoma or other chronic ocular condition that could be adversely affected by steroids (e.g., cataracts, increased ocular pressure from other causes, exophthalmos)
- Hypertension requiring treatment with one or more antihypertensive medications
- Congestive heart failure
- Current treatment for a seizure disorder
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation, including subjects not able to read or write
- Known coronary artery disease
- Active gastroparesis
- Cystic fibrosis
- Uncontrolled thyroid disease (TSH undetectable or > 10 mIU/L)
- Known abuse of alcohol
- A recent injury to body or limb, muscular disorder, use of any medication, any carcinogenic disease, or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the protocol
- Current use of a beta blocker medication
Laboratory results:
- HbA1c > 10.5%
- Abnormal liver or renal function (Transaminase >2 times the upper limit of normal, creatinine> 1.5 mg/dL)
- Labs drawn at screening visit or within three months prior to screening (for other purposes) will suffice for enrollment purposes
- Subject has skin conditions that, in the determination of the investigator, would preclude wearing the study devices (infusion set and sensor), in the abdomen. Examples include but are not limited to: psoriasis, burns, scaring, eczema, tattoos, and significant hypertrophy at sites of device wear; any known allergy to medical adhesives.
- Currently on long-term treatment using prednisone or other steroid
- If subject had been on short term treatment of prednisone, defer enrollment until underlying condition and prednisone treatment have resolved.
- Allergy to study drug, food or other study material.
- Clinically significant physical examination, laboratory test, or vital sign abnormality.
- Exposure to any investigational drug within 30 days.
- History of malignancy within the 5 years before screening (other than basal cell carcinoma).
- Participation in another pharmaceutical or device trial at the time of enrollment or during the study
- Having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Automated Insulin Delivery
Participants will use the Automated Insulin Delivery (AID) iAPS system for 2 weeks in the outpatient setting, and come to the clinical center twice for supervised stress assessments.
|
The AID system (iAPS) is comprised of an insulin pump, a Dexcom G6 continuous glucose monitoring sensor, and a smart phone that contains the algorithm and communicates with the other devices.
|
Active Comparator: SAP/PLGS
Participants will use their home pump with a CGM sensor (sensor augmented pump) or in Predictive Low Glucose Suspend (PLGS) mode if their home pump supports this mode, for 2 weeks in the outpatient setting, and come to the clinical center twice for supervised stress assessments.
|
Subjects will use their home insulin pump and a Dexcom G6 continuous glucose monitoring sensor.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time in target glucose range
Time Frame: 4 weeks
|
Time in target glucose range 70-180 mg/dL measured by CGM to determine safety and efficacy of the integrated system
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glucose < 70 mg/dL
Time Frame: 4 weeks
|
Percent time GGM glucose < 70 mg/dL
|
4 weeks
|
Glucose < 54 mg/dL
Time Frame: 4 weeks
|
Percent time GGM glucose < 54 mg/dL
|
4 weeks
|
Glucose > 180 mg/dL
Time Frame: 4 weeks
|
Percent time GGM glucose > 180 mg/dL
|
4 weeks
|
Glucose > 250 mg/dL
Time Frame: 4 weeks
|
Percent time GGM glucose > 250 mg/dL
|
4 weeks
|
Serious adverse events (SAE)
Time Frame: 4 weeks
|
The total number of serious adverse events during the clinical trial
|
4 weeks
|
Serious adverse device events (SADE)
Time Frame: 4 weeks
|
The total number of serious adverse events related to the study device use during the clinical trial
|
4 weeks
|
Adverse device effects (ADE)
Time Frame: 4 weeks
|
The total number of adverse device effects (ADE) during the clinical trial
|
4 weeks
|
Unanticipated adverse device effects (UADE)
Time Frame: 4 weeks
|
The total number of unanticipated adverse device effects (UADE) during the clinical trial
|
4 weeks
|
Change in glucose levels with stress induction
Time Frame: 4 weeks
|
Change in glucose levels with stress induction sessions (mg/dL)
|
4 weeks
|
Change in insulin requirements with stress induction
Time Frame: 4 weeks
|
Change in insulin requirements with stress induction sessions (units of insulin)
|
4 weeks
|
EDA stress detection
Time Frame: 4 weeks
|
Analysis of EDA to verify stress detection and correlation to glucose changes, both during the stress sessions and in the outpatient setting
|
4 weeks
|
Postprandial Time in Target Range
Time Frame: 4 weeks
|
Percent time within the target range of 70-180 mg/dl postprandial within 5 hours following meals
|
4 weeks
|
Salivary cortisol assessment
Time Frame: 4 weeks
|
Salivary cortisol assessment (nmol/l) during psychologic and physiologic stress induction
|
4 weeks
|
Empatica device-based assessment of psychologic and physiologic stress
Time Frame: 4 weeks
|
EDA Measurement of psychologic and physiologic stress from the Empatica E4 Watch
|
4 weeks
|
Trier Social Stress Test (TSST)
Time Frame: 4 weeks
|
Trier Social Stress Test (TSST) score at end of each test induction
|
4 weeks
|
Socially evaluated cold-pressor test (SECPT)
Time Frame: 4 weeks
|
Socially evaluated cold-pressor test (SECPT) score at end of each test induction
|
4 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total daily insulin use
Time Frame: 4 weeks
|
Total daily insulin use (units/day) during both use of SAP/PLGS and when using the iAPS
|
4 weeks
|
Total basal insulin use
Time Frame: 4 weeks
|
Total daily basal insulin use (units/day) during both use of SAP/PLGS and when using the iAPS
|
4 weeks
|
Total bolus insulin use
Time Frame: 4 weeks
|
Total daily bolus insulin use (units/day) during both use of SAP/PLGS and when using the iAPS
|
4 weeks
|
Sensor Use Time
Time Frame: 4 weeks
|
Total hours of CGM sensor use time during both use of SAP/PLGS and when using the iAPS
|
4 weeks
|
Closed-Loop Active Time
Time Frame: 2 weeks
|
Percent time (hours/day) of closed-loop use during the two weeks of iAPS use
|
2 weeks
|
Device Issues
Time Frame: 4 weeks
|
Total number of devices issues during the clinical trial
|
4 weeks
|
Questionnaire Score
Time Frame: 2 weeks
|
Questionnaire before and after AID use to assess technology acceptance, fear of hypoglycemia, diabetes associated distress (Likert Scale)
|
2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yogish Kudva, MBBS, Mayo Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Pinsker JE, Deshpande S, McCrady-Spitzer S, Church MM, Kaur RJ, Perez J, Desjardins D, Piper M, Reid C, Doyle FJ 3rd, Kudva YC, Dassau E. Use of the Interoperable Artificial Pancreas System for Type 1 Diabetes Management During Psychological Stress. J Diabetes Sci Technol. 2021 Jan;15(1):184-185. doi: 10.1177/1932296820948566. Epub 2020 Aug 12. No abstract available.
- Kaur RJ, Deshpande S, Pinsker JE, Gilliam WP, McCrady-Spitzer S, Zaniletti I, Desjardins D, Church MM, Doyle Iii FJ, Kremers WK, Dassau E, Kudva YC. Outpatient Randomized Crossover Automated Insulin Delivery Versus Conventional Therapy with Induced Stress Challenges. Diabetes Technol Ther. 2022 May;24(5):338-349. doi: 10.1089/dia.2021.0436. Epub 2022 Apr 25.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 25, 2019
Primary Completion (Actual)
November 6, 2020
Study Completion (Actual)
November 6, 2020
Study Registration Dates
First Submitted
October 25, 2019
First Submitted That Met QC Criteria
October 25, 2019
First Posted (Actual)
October 29, 2019
Study Record Updates
Last Update Posted (Actual)
December 1, 2020
Last Update Submitted That Met QC Criteria
November 28, 2020
Last Verified
November 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-006965
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on iAPS
-
Laval UniversityMaltais, Francois, M.D.; Saey, Didier, M.D.; Dr Louis Laviolette; Dr Thomas SimilowskiUnknownChronic Obstructive Pulmonary DiseaseCanada
-
Sansum Diabetes Research InstituteHarvard University; Harvard School of Public Health (HSPH)Completed
-
Sansum Diabetes Research InstituteMayo Clinic; Icahn School of Medicine at Mount Sinai; Harvard UniversityCompletedType 1 Diabetes | PregnancyUnited States
-
Sansum Diabetes Research InstituteNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Harvard... and other collaboratorsCompletedType 1 DiabetesUnited States
-
Istituto Auxologico ItalianoRecruitingAnorexia Nervosa | Parkinson DiseaseItaly
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Not yet recruitingHead and Neck Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage III... and other conditions